This portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event. Archived information may be superseded by more recent information we have disclosed in later presentations, press releases, filings with the Securities and Exchange Commission or otherwise. Archived information may contain forward-looking statements. Actual results may materially differ based on several factors, including those described in the archived information, press releases and our filings with the SEC.
2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
- December 28, 2005
Targacept and AstraZeneca Announce Global License and Research Collaboration Agreement - November 15, 2005
Targacept Presents Data at the 35th Annual Meeting of the Society for Neuroscience - July 06, 2005
Targacept Reports Positive Phase 2 Data on Ispronicline, a Novel Small Molecule Being Developed for Treatment of Alzheimer’s Disease and Age Associated Memory Impairment - June 30, 2005
Targacept Compounds Show Long-lasting Improvement In Cognition, According to Trends in Pharmacological Sciences Publication - June 02, 2005
Targacept to Present at Pacific Growth Equities 2005 Life Science Growth Conference - April 28, 2005
Targacept to present at the Deutsche Bank 30th Annual Health Care Conference - March 31, 2005
Targacept to Present at CIBC Conference - March 29, 2005
Targacept Presents Promising Results at the 7th International Conference on Alzheimer's and Parkinson's Disease - March 23, 2005
Targacept Named One of the Best Employers in North Carolina